Ajanta Pharma Share Price Up 13% In 3 Months; Motilal Oswal Sees 16% Upside; Time To Buy? Check Target Price

Ajanta Share Price Today: Shares of Ajanta Pharma Limited continued to trade in green on Tuesday, building on to their strong momentum over the past three months. The pharmaceutical company shares have surged nearly 16% in the last three months.

Ajanta Pharmaceuticals is likely to benefit from the multiple strategic initiatives across focus branded generics markets of India, Asia, and Africa, noted Motilal Oswal Financial Services in its report on Tuesday.

Ajanta Pharma shares were trading 2% higher at Rs 2740 per share on BSE with a market capitalisation of Rs 34,242.36 crore on BSE at 10:32 am. The stock had touched an intraday high of Rs 2748.85 per share and an intraday low of Rs 2687.20 per share.

Ajanta Pharma Share Price Recommendation

Motilal Oswal has given a buy rating to the pharmaceutical sector stock, indicating long-term gains for the investors. The company's plans to expand its therapy coverage and focus to shift towards chronic indications is likely to support its long-term sustainable growth.

"We expect a revenue/EBITDA/PAT CAGR of 11%/15%/16% to reach INR65b/ INR19b/INR14b over FY26-28. We estimate potential annualised sales from the semaglutide opportunity in Asia and Africa at USD25-30m from 2HFY28 onwards. Assuming a gross margin of ~70% and limited incremental operating costs, the EBITDA margin for this product should be healthy at 50-55%, driving incremental profitability for AJP," noted the brokerage in its report.

Ajanta Pharma Share Price Target

The brokerage has given a 'Buy' rating with a target price of Rs 3,145 per share, indicating nearly 17% upside in its valuation in the long term. "We value AJP at 30x 12M forward earnings to arrive at our TP of INR3,145. Reiterate BUY," noted MOFSL in its report.

Ajanta Pharma Share Price Trend

Ajanta Pharma shares were trading in green during Tuesday's intraday trade. Ajanta Pharma shares had touched a 52-week high mark of Rs 3091.65 per share on 7 January 2025. The stock had dipped to a 52-week low of Rs 2022.05 per share on 7 April 2025.

The pharma sector stock has a return on equity (RoE) of 26.93%. The stock has given a nearly 13.99% return in three months, and declined nearly 7.21% in one year. The stock has surged around 31% in two years.